Linezolid in the treatment of drug-resistant tuberculosis: The way forward?

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 6, 2014, Pages 631-632

  Yew, Wing Wai ^a   Lange, Christoph ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLAVULANIC ACID; CLOFAZIMINE; LINEZOLID; MEROPENEM; ACETAMIDE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATE; CROSS RESISTANCE; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEMATOLOGIC DISEASE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NEUROTOXICITY; PRIORITY JOURNAL; SYSTEMATIC REVIEW (TOPIC); DRUG EFFECTS; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ACETAMIDES; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84901277433     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.14.0191     Document Type: Editorial

References (20)

1. Chang K C, Yew W W. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012. Respirology 2013; 18: 8-21.
2. Yew WW, Nuermberger E. High-dose fluoroquinolones in short-course regimens for treatment of MDR-TB: the way forward? Int J Tuberc Lung Dis 2013; 17: 853-854.
3. Dooley K E, Obuku E A, Durakovic N, Belitsky V, Mitnick C, Nuermberger E L; Efficacy Subgroup, RESIST-TB. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis 2013; 207: 1352-1358.
4. Chang K C, Yew W W, Tam C M, Leung C C. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother 2013; 57: 4097-4104.
5. Gopal M, Padayatchi N, Metcalfe J Z, O'Donnell M R. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013; 17: 1001-1007.
6. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
7. Eker B, Ortmann J, MiglioriGB, et al.; German TBNET Group. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerging Infect Dis 2008; 14: 1700-1706.
8. Migliori G B, Eker B, Richardson M D, et al.; TBNET Study Group. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
9. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16: 447-454
10. Sotgiu G, Centis R, D' Ambrosio L, et al. Efficacy, safety, and tolerability of linezolid containing regimens in treating MDRTB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
11. KohWJ, Kang Y R, Jeon K, et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother 2012; 67: 1503-1507.
12. Lee M, Lee J, Carroll M W, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
13. Huang T S, Liu Y C, Sy C L, Chen Y S, Tu H Z, Chen B C. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrob Agents Chemother 2008; 52: 2226-2227.
14. Wallis R S, Jakubiec W M, Kumar V, et al. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J Infect Dis 2010; 202: 745-751.
15. Balasubramanian V, Solapure S, Iyer H, et al. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob Agents Chemother 2014; 58: 495-502.
16. Chang K C, Yew W W, Cheung S W, et al. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? Antimicrob Agents Chemother 2013; 57: 3445-3449.
17. Schaaf H S, Willemse M, Donald P R. Long-term linezolid treatment in a young child with extensively drug-resistant tuberculosis. Pediatr Infect Dis J 2009; 28: 748-750.
18. Yew W W, Cynamon M, Zhang Y. Emerging drugs for the treatment of tuberculosis. Expert Opin Emerg Drugs 2011; 16: 1-21.
19. Singla R, Caminero J A, Jaiswal A, et al. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. Eur Respir J 2012; 39: 956-962.
20. Chang K C, Leung C C, Daley C L. Linezolid for multidrug-resistant tuberculosis. Lancet Infect Dis 2012; 12: 502-503.